316 related articles for article (PubMed ID: 30126230)
1. The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients.
Sáenz-Cuesta M; Alberro A; Muñoz-Culla M; Osorio-Querejeta I; Fernandez-Mercado M; Lopetegui I; Tainta M; Prada Á; Castillo-Triviño T; Falcón-Pérez JM; Olascoaga J; Otaegui D
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126230
[TBL] [Abstract][Full Text] [Related]
2. Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment.
Ebrahimkhani S; Beadnall HN; Wang C; Suter CM; Barnett MH; Buckland ME; Vafaee F
Mol Neurobiol; 2020 Feb; 57(2):1245-1258. PubMed ID: 31721043
[TBL] [Abstract][Full Text] [Related]
3. Sulfatides in extracellular vesicles isolated from plasma of multiple sclerosis patients.
Moyano AL; Li G; Boullerne AI; Feinstein DL; Hartman E; Skias D; Balavanov R; van Breemen RB; Bongarzone ER; Månsson JE; Givogri MI
J Neurosci Res; 2016 Dec; 94(12):1579-1587. PubMed ID: 27557608
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
Blumenfeld S; Staun-Ram E; Miller A
J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
[TBL] [Abstract][Full Text] [Related]
5. Assessment of expression profile of microRNAs in multiple sclerosis patients treated with fingolimod.
Mazdeh M; Kordestani H; Komaki A; Eftekharian MM; Arsang-Jang S; Branicki W; Taheri M; Ghafouri-Fard S
J Mol Neurosci; 2020 Aug; 70(8):1274-1281. PubMed ID: 32215780
[TBL] [Abstract][Full Text] [Related]
6. Expression Profile of Selected MicroRNAs in the Peripheral Blood of Multiple Sclerosis Patients: a Multivariate Statistical Analysis with ROC Curve to Find New Biomarkers for Fingolimod.
Eftekharian MM; Komaki A; Mazdeh M; Arsang-Jang S; Taheri M; Ghafouri-Fard S
J Mol Neurosci; 2019 May; 68(1):153-161. PubMed ID: 30895441
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
Angerer IC; Hecker M; Koczan D; Roch L; Friess J; Rüge A; Fitzner B; Boxberger N; Schröder I; Flechtner K; Thiesen HJ; Winkelmann A; Meister S; Zettl UK
CNS Neurosci Ther; 2018 Mar; 24(3):193-201. PubMed ID: 29314605
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.
Miyazaki Y; Niino M; Takahashi E; Suzuki M; Mizuno M; Hisahara S; Fukazawa T; Amino I; Nakano F; Nakamura M; Akimoto S; Minami N; Fujiki N; Doi S; Shimohama S; Terayama Y; Kikuchi S
Clin Immunol; 2018 Feb; 187():95-101. PubMed ID: 29079163
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
[TBL] [Abstract][Full Text] [Related]
10. Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
Hawke S; Zinger A; Juillard PG; Holdaway K; Byrne SN; Grau GE
J Neuroimmunol; 2020 Dec; 349():577392. PubMed ID: 33007647
[TBL] [Abstract][Full Text] [Related]
11. Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod.
Montarolo F; Perga S; Martire S; Brescia F; Caldano M; Lo Re M; Panzica G; Bertolotto A
Eur J Neurol; 2019 Apr; 26(4):667-672. PubMed ID: 30565812
[TBL] [Abstract][Full Text] [Related]
12. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
Piehl F; Kockum I; Khademi M; Blennow K; Lycke J; Zetterberg H; Olsson T
Mult Scler; 2018 Jul; 24(8):1046-1054. PubMed ID: 28627962
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis treatment effects on plasma cytokine receptor levels.
Bedri SK; Fink K; Manouchehrinia A; Lundström W; Kockum I; Olsson T; Hillert J; Glaser A
Clin Immunol; 2018 Feb; 187():15-25. PubMed ID: 28941836
[TBL] [Abstract][Full Text] [Related]
14. A First Phenotypic and Functional Characterization of Placental Extracellular Vesicles from Women with Multiple Sclerosis.
Martire S; Montarolo F; Spadaro M; Perga S; Sforza ML; Marozio L; Frezet F; Bruno S; Chiabotto G; Deregibus MC; Camussi G; Botta G; Benedetto C; Bertolotto A
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809077
[TBL] [Abstract][Full Text] [Related]
15. Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
Fenoglio C; De Riz M; Pietroboni AM; Calvi A; Serpente M; Cioffi SM; Arcaro M; Oldoni E; Scarpini E; Galimberti D
J Neuroimmunol; 2016 Oct; 299():81-83. PubMed ID: 27725128
[TBL] [Abstract][Full Text] [Related]
16. Potential Roles of Extracellular Vesicles as Biomarkers and a Novel Treatment Approach in Multiple Sclerosis.
Gutiérrez-Fernández M; de la Cuesta F; Tallón A; Cuesta I; Fernández-Fournier M; Laso-García F; Gómez-de Frutos MC; Díez-Tejedor E; Otero-Ortega L
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445717
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
[TBL] [Abstract][Full Text] [Related]
18. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
[TBL] [Abstract][Full Text] [Related]
19. Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.
Killestein J; Leurs CE; Hoogervorst ELJ; van Eijk J; Mostert JP; van den Eertwegh AJM; Uitdehaag BMJ
Neurology; 2017 Aug; 89(9):970-972. PubMed ID: 28768850
[No Abstract] [Full Text] [Related]
20. MicroRNAs in extracellular vesicles: potential cancer biomarkers.
Kinoshita T; Yip KW; Spence T; Liu FF
J Hum Genet; 2017 Jan; 62(1):67-74. PubMed ID: 27383658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
